Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05132244 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Monitoring and Managing Glucose Levels in People With Pancreatic Cancer

Study acronym: PEGASUS
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 5 months later Apr 2027 → Oct 2028
Primary endpoint added 1 → 2 primary endpoints
See other at-risk trials from British Columbia Cancer Agency

Record History

  1. Primary and study completion pushed from Apr 2027 to Oct 2028 Primary endpoint(s) modified · Interventions modified · Trial arms changed: 2 → 1 · 3 morev9 Show 6 more changesShow less
    • Primary endpoint(s) modified
    • Interventions modified
    • Trial arms changed: 2 → 1
    • Eligibility criteria shortened, about 22 words
    • Secondary endpoints revised (3)
    • Publications: 30 to 32

    See this version in full on ClinicalTrials.gov ↗

  2. Primary completion date: Apr 2026 to Apr 2027 Study sites: 1 to 2 · Collaborators: 1 to 3v8 Show 2 more changesShow less
    • Study sites: 1 to 2
    • Collaborators: 1 to 3

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion date: Feb 2026 to Apr 2026 Start date changed from estimate of Feb 2024 to Apr 16, 2024v7 Show 1 more changeShow less
    • Start date changed from estimate of Feb 2024 to Apr 16, 2024
  4. Trial status: Not Yet Recruiting to Recruiting Start date: Oct 2023 to Feb 2024 · Study sites: 0 to 1 · Primary completion date: Oct 2025 to Feb 2026 · 1 morev6 Show 4 more changesShow less
    • Start date: Oct 2023 to Feb 2024
    • Study sites: 0 to 1
    • Primary completion date: Oct 2025 to Feb 2026
    • Completion date: Dec 2026 to Apr 2027
  5. Start date: Jun 2023 to Oct 2023 Primary completion date: Jun 2025 to Oct 2025v5 Show 1 more changeShow less
    • Primary completion date: Jun 2025 to Oct 2025
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: Sep 2024 to Jun 2025 Start date: Sep 2022 to Jun 2023 · Completion date: Dec 2025 to Dec 2026v4 Show 2 more changesShow less
    • Start date: Sep 2022 to Jun 2023
    • Completion date: Dec 2025 to Dec 2026
  2. Start date: May 2022 to Sep 2022v3
  3. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will investigate the prevalence of hyperglycemia (high blood sugar) in approximately 50 participants with pancreatic cancer. Sugar levels will be monitored with blood draws prior to each cycle of anti-cancer treatment until treatment ends or the participant's cancer worsens. Participants may receive any first-line systemic therapy for pancreatic cancer, including treatments given as part of another clinical trial. If treatment is needed to manage blood sugar levels, the treatment will be given according to the standard of care. All participants will be enrolled into the same group.
Trial Details
NCT Number NCT05132244
Lead Sponsor British Columbia Cancer Agency
Collaborators: University of British Columbia, Lustgarten Foundation, University Health Network, Toronto
Conditions Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Hyperglycemia
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov